The management of spasticity can be complex. A common treatment for focal spasticity is botulinum toxin-A (BoNT-A)
therapy. Breakthrough symptoms between injection intervals are distressing to patients and may have a significant impact on quality of life. This video reviews how patients are affected and discusses multi-modality approaches to managing disruptive symptoms and improving outcomes for patients.
Speakers had full editorial control of content. The views and opinions expressed in this video are those of the speaker and do not necessarily reflect those of the sponsor.
This program has received an unrestricted educational grant or in-kind support from Ipsen Biopharmaceuticals Canada Inc.